Direct compression of phenobarbital veterinary tablets is rarely selected when the API fraction exceeds 25% w/w because micronized phenobarbital exhibits cohesive flow and can adhere to tooling on high-speed rotary presses. Wet granulation therefore remains the controlling manufacturing route for 15 mg, 30 mg, 60 mg, and 100 mg canine epilepsy tablets, with final blend ratios typically in the range of 10–45% w/w phenobarbital depending on tablet weight and the particle-binding capacity of lactose monohydrate or dibasic calcium phosphate dihydrate fillers. A representative granulation formula includes pregelatinized starch at 3–8% w/w, croscarmellose sodium at 1–4% w/w, and magnesium stearate at 0.25–0.75% w/w, with purified water or starch paste as the granulation fluid at 5–12% w/w of dry blend mass; the wet mass is passed through a 1.0–2.0 mm conical mill and dried in a fluid-bed dryer with inlet air at 50–65°C to a loss-on-drying endpoint ≤2.0% w/w. Compliance for this route is anchored to USP <905> uniformity of dosage units, USP <711> dissolution, 21 CFR 211.110 in-process blend uniformity, and VICH GL18 residual solvent limits where isopropanol or ethanol is introduced during granulation; the API lot must also meet Ph. Eur. 0201 or USP Phenobarbital monograph identity, assay, related substances, and loss on drying before release. The dried granulate is milled through an 0.8–1.25 mm screen, lubricated in a bin blender for 3–10 min, and compressed on a rotary tablet press with precompression force 2–5 kN and main compression force 8–18 kN. Ejection force is monitored because residual moisture above 2.5% w/w or lubricant depletion produces frictional heating and sticking on punch faces; tablet hardness and friability are controlled against machine capability, and the score line is tested according to USP <1217> or an equivalent equipment-specific method. Terminal products are scored tablets containing 15 mg, 30 mg, 60 mg, or 100 mg phenobarbital for chronic oral maintenance in dogs with idiopathic epilepsy, packaged in amber glass or high-density polyethylene bottles with child-resistant closures and controlled-substance labelling under 21 CFR 1308.14.

Why Is Aseptic Filtration Pressure Drop a Leading Signal in Phenobarbital Injection Lines?

Phenobarbital sodium injection for status epilepticus in dogs and cats is prepared as a sterile solution because the free acid has poor aqueous solubility below pH 8.0; propylene glycol-water mixtures are used to maintain a filterable solution at phenobarbital concentrations between 30 mg/mL and 65 mg/mL. A representative formulation ratio comprises phenobarbital sodium equivalent to phenobarbital 30–65 mg/mL, benzyl alcohol 1.0–2.0% v/v, propylene glycol 60–80% v/v, and water for injection q.s., with pH adjusted to 8.5–10.0 using sodium hydroxide or hydrochloric acid. The compliance framework includes 21 CFR 211.113(b) sterility assurance, USP <71> sterility testing, USP <85> bacterial endotoxin limits, USP <788> particulate matter in injections, USP <790> visible particulates, and EU GMP Annex 1 for Grade A/B aseptic filling of open ampoules or vials; controlled-substance storage and reconciliation is governed by 21 CFR 1301.71 through 1301.76 and Schedule IV registration under 21 CFR 1308.14. Downstream processing begins with nitrogen-purged dissolution of the sodium salt in prechilled solvent, followed by 0.45 µm clarification and 0.22 µm sterile filtration through PVDF or PES membrane capsules; filter pressure drop is tracked across the batch because propylene glycol raises solution viscosity, and a rising differential above the qualified bubble-point or diffusive-flow window signals gel-like particulates, membrane fouling, or filter saturation before sterility risk accumulates. Glass vials or ampoules are depyrogenated in a dry-heat tunnel at 250°C for not less than 30 min; rubber stoppers are washed with water for injection, siliconised, and autoclaved. Filling is performed with a peristaltic or rotary piston machine into amber Type I glass containers under Grade A laminar airflow, with fill-volume checks at 15-minute intervals and 100% automated visual inspection after sealing. Terminal products are injectable solutions of 30 mg/mL, 60 mg/mL, or 65 mg/mL phenobarbital for intravenous use in emergency seizure control; a multi-dose preserved presentation is not released unless antimicrobial effectiveness is demonstrated according to USP <51> and in-use stability is confirmed.

In feline and small-canine patients whose body mass does not align with fixed tablet strengths, phenobarbital oral liquids are manufactured or extemporaneously compounded at 4 mg/mL to 10 mg/mL so that 0.5 mg/kg dose increments can be withdrawn with a 0.5 mL or 1.0 mL oral syringe. A suspension vehicle rather than a true solution is often selected when the API is supplied as micronized free acid because phenobarbital free acid has a pKa near 7.3, and complete dissolution requires alkaline pH that may reduce palatability and increase susceptibility to carbon dioxide uptake and pH drift. The formulation addition ratio for a 5 mg/mL compounded suspension includes phenobarbital USP 0.5% w/v, glycerin 10–20% v/v, propylene glycol 5–15% v/v, sodium citrate or phosphate buffer to maintain pH 6.5–7.5, microcrystalline cellulose/carboxymethylcellulose sodium 0.5–1.0% w/v as suspending agent, and sodium benzoate 0.1–0.2% w/v with citric acid as preservative. Compliance is tied to USP <795> for non-sterile compounding, USP <800> for hazardous drug containment and surface wipe limits, 21 CFR 211.67 for equipment cleaning of non-dedicated lines, USP <51> for antimicrobial effectiveness when a multi-dose container is used, and 21 CFR 1308.14 Schedule IV inventory and disposal controls. The production process uses high-shear dispersion of the suspending agent and preservative in purified water, separate addition of a co-solvent phase containing phenobarbital, pH adjustment after hydration, and homogenization at 5,000–10,000 rpm for 5–15 min; the resulting suspension is vacuum-deaerated to reduce air entrapment, then viscosity is checked on a Brookfield-type rotational viscometer before volumetric piston filling into amber PET or glass bottles with child-resistant closures. Terminal products are oral suspensions or solutions at 4 mg/mL, 5 mg/mL, or 10 mg/mL for cats and small dogs, with a shake-well statement, light-protective packaging, and a beyond-use date assigned from real-time physico-chemical stability data rather than extrapolation alone.

When Capsule Weight Variation Is Masked by Phenobarbital Particle Size Shifts

Phenobarbital hard capsules for canine long-term maintenance are filled from a low-API-fraction trituration rather than from pure micronized API because the pure powder’s cohesive nature and particle-size distribution can shift during hopper vibration, producing dose uniformity excursions that are not detected by average fill weight alone. The addition ratio for capsules in the 15 mg to 100 mg strength range often places phenobarbital at 3–25% w/w of total fill mass, diluted with lactose monohydrate or mannitol 60–90% w/w, sodium starch glycolate 1–4% w/w, and magnesium stearate 0.25–0.5% w/w; the ratio depends on capsule size 4 through 0 and target fill weights of 120–300 mg. Industry compliance includes USP <905> uniformity of dosage units for filled capsules, USP <711> dissolution, 21 CFR 211.84 component qualification, 21 CFR 211.110 in-process fill-weight and content uniformity monitoring, and VICH GL18 residual solvent certification of incoming API. Mixing is performed by geometric dilution in a V-blender or bin blender: the API is pre-sieved through a 40-mesh screen, blended with an equal mass of filler for 5 min, then the remainder of the filler is added and blended for 10–20 min, with lubricant added only in the final 2–5 min to prevent hydrophobic overcoating and dissolution slowing. Capsule filling is carried out on a dosator or tamping-pin machine with 100% weight sorting and periodic content uniformity sampling after machine stoppages; empty capsule shells are qualified for powder retention and for moisture content between 12% and 16% w/w to prevent brittleness or telescoping. Terminal products are hard gelatin or hypromellose capsules containing 15 mg, 30 mg, 60 mg, or 100 mg phenobarbital for maintenance therapy, with the shell type documented because switching between gelatin and hypromellose requires re-validation of dissolution due to shell cross-linking or pH-dependent rupture differences.

Before phenobarbital is compressed into low-dose tablets or filled into capsules on high-speed lines, a powder or granulated premix may be manufactured as a segregated intermediate to reduce dust, improve powder flow, and normalise API distribution across the batch. The granulated premix is prepared with phenobarbital at 5–30% w/w, lactose monohydrate 60–85% w/w, povidone K30 2–4% w/w as binder, crospovidone 1–3% w/w as disintegrant, and colloidal silicon dioxide 0.2–0.5% w/w as glidant; the binder is delivered as a 5–8% w/w aqueous solution during top-spray fluid-bed granulation. Compliance for this intermediate is governed by 21 CFR 211.80 and 211.84 for component handling, 21 CFR 211.110 for granulation moisture and particle-size in-process limits, USP <811> powder fineness, USP <1174> powder flow, and VICH GL18 residual solvent control. Processing uses a high-shear granulator or fluid-bed top-spray system with inlet air at 55–70°C, product temperature 28–38°C, and spray rate 5–20 g/min/kg of bed mass; the wet granulate is dried to a loss-on-drying endpoint ≤2.5% w/w and milled through a 0.8–1.4 mm screen before final blending with lubricant for compression or encapsulation. Terminal packages are granulated premix drums with double polyethylene liners or intermediate bulk containers, labelled with the phenobarbital concentration per gram, lot number, and controlled-substance warning, for subsequent validated conversion into tablets or hard capsules. Published data for this specific configuration is limited where the equipment train differs from the vendor-qualified granulator; therefore the granulation end-point limits are established against equipment torque or product temperature rather than a single universal moisture value.